NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.65 +0.10 (+0.57 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$17.65
Today's Range$17.40 - $17.85
52-Week Range$5.50 - $22.75
Volume29,100 shs
Average Volume52,968 shs
Market Capitalization$311.29 million
P/E Ratio-9.92
Dividend YieldN/A
Beta3.48

About Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group logoCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884

Debt

Debt-to-Equity RatioN/A
Current Ratio9.36
Quick Ratio9.36

Price-To-Earnings

Trailing P/E Ratio-9.92
Forward P/E Ratio-10.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$340,000.00
Price / Sales907.94
Cash FlowN/A
Price / CashN/A
Book Value$4.65 per share
Price / Book3.80

Profitability

EPS (Most Recent Fiscal Year)($1.78)
Net Income$-25,490,000.00
Net Margins-9,594.83%
Return on Equity-45.67%
Return on Assets-42.58%

Miscellaneous

Employees125
Outstanding Shares17,490,000

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How will Cellular Biomedicine Group's stock buyback program work?

Cellular Biomedicine Group declared that its board has authorized a share repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $10,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board believes its stock is undervalued.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.05. The biotechnology company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.10 million. Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%. View Cellular Biomedicine Group's Earnings History.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Cellular Biomedicine Group.

What price target have analysts set for CBMG?

2 brokers have issued 1 year price objectives for Cellular Biomedicine Group's stock. Their predictions range from $18.00 to $32.00. On average, they expect Cellular Biomedicine Group's stock price to reach $25.00 in the next twelve months. View Analyst Ratings for Cellular Biomedicine Group.

What are Wall Street analysts saying about Cellular Biomedicine Group stock?

Here are some recent quotes from research analysts about Cellular Biomedicine Group stock:
  • 1. According to Zacks Investment Research, "Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California. " (5/23/2018)
  • 2. Maxim Group analysts commented, "As Gilead pays $12 Billion for the planned acquisiton of Kite (KITE – $178.28 – Hold) and the market shifts focus to the remaining stand-alone CAR-T players such as JUNO (JUNO – $43.67 – Buy) and bluebird (BLUE – $103.88 – Buy) we see an opportunity with CBMG in China." (8/29/2017)

Who are some of Cellular Biomedicine Group's key competitors?

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:
  • Mr. Bizuo Liu, Chief Exec. Officer, Interim Chief Financial Officer and Director (Age 53)
  • Dr. Yihong Yao Ph.D., BS, Chief Scientific Officer (Age 50)
  • Mr. Andrew K. Chan J.D., MBA, Sr. VP of Legal & Corp. Devel. and Board Sec. (Age 60)
  • Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
  • Dr. Wen Tao Liu Ph.D., Strategic Advisor and Director (Age 62)

Has Cellular Biomedicine Group been receiving favorable news coverage?

News articles about CBMG stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.22%) and Tibra Equities Europe Ltd (0.16%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

Which major investors are buying Cellular Biomedicine Group stock?

CBMG stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and Northern Trust Corp. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $17.65.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $311.29 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (CBMG)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellular Biomedicine Group (NASDAQ:CBMG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Cellular Biomedicine Group in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 41.64%. The high price target for CBMG is $32.00 and the low price target for CBMG is $18.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.502.502.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.00$25.00$18.00$18.00
Price Target Upside: 41.64% upside29.20% upside13.25% downside100.00% upside

Cellular Biomedicine Group (NASDAQ:CBMG) Consensus Price Target History

Price Target History for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ:CBMG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2018B. RileySet Price TargetBuy$32.00MediumView Rating Details
3/6/2018Maxim GroupReiterated RatingHoldMediumView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings History and Estimates Chart

Earnings by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings Estimates

2018 EPS Consensus Estimate: ($2.10)
2019 EPS Consensus Estimate: ($2.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.47)($0.47)($0.47)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.54)($0.54)($0.54)
Q4 20181($0.57)($0.57)($0.57)
Q1 20191($0.59)($0.59)($0.59)
Q2 20191($0.60)($0.60)($0.60)
Q3 20191($0.62)($0.62)($0.62)
Q4 20191($0.65)($0.65)($0.65)

Cellular Biomedicine Group (NASDAQ CBMG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.47)N/AView Earnings Details
5/7/2018Q1 2018($0.46)($0.51)$0.10 million$0.05 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.40)($0.48)$0.07 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.43)$0.11 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.43)$0.06 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.43)$0.10 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.43)($0.43)$0.06 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.54)$0.01 millionViewN/AView Earnings Details
8/9/2016Q216($0.52)$0.07 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.35)$0.49 millionViewN/AView Earnings Details
3/14/2016Q415($0.42)($0.43)$1.50 million$0.62 millionViewN/AView Earnings Details
11/13/2015Q3($0.43)($0.44)$0.63 millionViewN/AView Earnings Details
8/14/2015Q215($0.37)($0.44)$0.66 millionViewN/AView Earnings Details
5/18/2015Q115($0.40)($0.39)$0.60 millionViewN/AView Earnings Details
3/31/2015($0.32)($0.57)ViewN/AView Earnings Details
11/19/2014Q3 2014($0.30)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.29)$0.12 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cellular Biomedicine Group (NASDAQ:CBMG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 4.09%
Insider Trading History for Cellular Biomedicine Group (NASDAQ:CBMG)
Institutional Ownership by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Wen Tao LiuDirectorSell10,400$20.10$209,040.00223,476View SEC Filing  
12/22/2017Andrew K. ChanSVPBuy8,333$12.00$99,996.00View SEC Filing  
12/22/2017Tony LiuCEOBuy29,167$12.00$350,004.00View SEC Filing  
12/22/2017Yihong YaoInsiderBuy4,167$12.00$50,004.00View SEC Filing  
6/6/2017Tony LiuCEOBuy10,000$6.83$68,300.00119,825View SEC Filing  
2/22/2016Andrew K ChanSVPSell1,307$18.22$23,813.54147,054View SEC Filing  
2/17/2016Andrew K. ChanSVPSell1,516$17.76$26,924.16145,747View SEC Filing  
1/21/2016Andrew K. ChanSVPSell2,812$12.90$36,274.80145,747View SEC Filing  
12/21/2015Andrew K. ChanSVPSell12,812$21.94$281,095.28142,945View SEC Filing  
11/23/2015Andrew K. ChanSVPSell5,332$20.64$110,052.48155,757View SEC Filing  
10/21/2015Wei (William) CaoCEOSell20,000$19.59$391,800.00222,518View SEC Filing  
10/20/2015Andrew K. ChanSVPSell5,215$20.20$105,343.00159,793View SEC Filing  
9/21/2015Andrew K. ChanSVPSell27,927$20.80$580,881.60162,196View SEC Filing  
12/23/2014Pak To LeungMajor ShareholderSell142,857$14.00$1,999,998.00View SEC Filing  
6/26/2014David BolocanDirectorBuy10,000$5.00$50,000.00View SEC Filing  
5/22/2014Tony LiuCFOBuy100,000$5.00$500,000.00View SEC Filing  
7/23/2013Keith WongDirectorSell320,050$0.13$41,606.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cellular Biomedicine Group (NASDAQ CBMG) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Forecast for Cellular Biomedicine Group Inc Issued By B. Riley (CBMG)Q2 2018 Earnings Forecast for Cellular Biomedicine Group Inc Issued By B. Riley (CBMG)
www.americanbankingnews.com - May 23 at 6:44 AM
Cellular Biomedicine Group Inc to Post Q1 2019 Earnings of ($0.59) Per Share, B. Riley Forecasts (CBMG)Cellular Biomedicine Group Inc to Post Q1 2019 Earnings of ($0.59) Per Share, B. Riley Forecasts (CBMG)
www.americanbankingnews.com - May 22 at 7:48 AM
Cellular Biomedicine Group (CBMG) Given a $32.00 Price Target at B. RileyCellular Biomedicine Group (CBMG) Given a $32.00 Price Target at B. Riley
www.americanbankingnews.com - May 21 at 11:05 AM
Cellular Biomedicine Gr (CBMG) Downgraded by BidaskClubCellular Biomedicine Gr (CBMG) Downgraded by BidaskClub
www.americanbankingnews.com - May 10 at 1:02 PM
Cellular Biomedicine Gr (CBMG) Announces  Earnings Results, Misses Estimates By $0.05 EPSCellular Biomedicine Gr (CBMG) Announces Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
Cellular Biomedicine: 1Q Earnings SnapshotCellular Biomedicine: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:34 AM
Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational ProgressCellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
finance.yahoo.com - May 8 at 9:34 AM
Should You Be Content With Cellular Biomedicine Group Inc’s (NASDAQ:CBMG) Earnings Growth?Should You Be Content With Cellular Biomedicine Group Inc’s (NASDAQ:CBMG) Earnings Growth?
finance.yahoo.com - May 7 at 4:27 PM
Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of StockholdersCellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders
finance.yahoo.com - April 30 at 9:50 AM
Cellular Biomedicine Gr (CBMG) Scheduled to Post Quarterly Earnings on MondayCellular Biomedicine Gr (CBMG) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:35 AM
 Cellular Biomedicine (CBMG) Given $32.00 Consensus Target Price by Analysts Cellular Biomedicine (CBMG) Given $32.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 12 at 11:19 PM
Cellular Biomedicine (CBMG) Director Sells $209,040.00 in StockCellular Biomedicine (CBMG) Director Sells $209,040.00 in Stock
www.americanbankingnews.com - April 12 at 4:33 PM
ValuEngine Upgrades Cellular Biomedicine (CBMG) to HoldValuEngine Upgrades Cellular Biomedicine (CBMG) to Hold
www.americanbankingnews.com - April 5 at 2:03 PM
Cellular Biomedicine (CBMG) Upgraded to "Buy" at BidaskClubCellular Biomedicine (CBMG) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 29 at 4:44 PM
Maxim Group Downgrades Cellular Biomedicine (CBMG) to HoldMaxim Group Downgrades Cellular Biomedicine (CBMG) to Hold
www.americanbankingnews.com - March 25 at 10:22 PM
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of StockholdersCellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
finance.yahoo.com - March 23 at 9:36 AM
 Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Buy" from Brokerages Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 22 at 3:24 PM
Contrasting VIVUS (VVUS) & Cellular Biomedicine Group (CBMG)Contrasting VIVUS (VVUS) & Cellular Biomedicine Group (CBMG)
www.americanbankingnews.com - March 20 at 11:46 AM
Wired News – Cellular Biomedicines 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOAWired News – Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA
finance.yahoo.com - March 20 at 9:53 AM
Cellular Biomedicine Groups (CBMG) Buy Rating Reaffirmed at B. RileyCellular Biomedicine Group's (CBMG) Buy Rating Reaffirmed at B. Riley
www.americanbankingnews.com - March 16 at 4:26 PM
B. Riley Weighs in on Cellular Biomedicine Group Incs Q1 2018 Earnings (CBMG)B. Riley Weighs in on Cellular Biomedicine Group Inc's Q1 2018 Earnings (CBMG)
www.americanbankingnews.com - March 12 at 2:48 AM
Cellular Biomedicine Group (CBMG) Earns Buy Rating from Analysts at B. RileyCellular Biomedicine Group (CBMG) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - March 10 at 8:48 PM
Zacks: Cellular Biomedicine Group Inc (CBMG) Given Consensus Rating of "Hold" by BrokeragesZacks: Cellular Biomedicine Group Inc (CBMG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 5:24 AM
Cellular Biomedicine Group (CBMG) Releases  Earnings Results, Misses Expectations By $0.08 EPSCellular Biomedicine Group (CBMG) Releases Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - March 7 at 10:24 AM
BRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational ProgressBRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress
www.reuters.com - March 7 at 9:46 AM
Cellular Biomedicine Group (CBMG) Given Hold Rating at Maxim GroupCellular Biomedicine Group (CBMG) Given Hold Rating at Maxim Group
www.americanbankingnews.com - March 6 at 3:32 PM
Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational ProgressCellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress
finance.yahoo.com - March 6 at 9:31 AM
Cellular Biomedicine Group (CBMG) Set to Announce Earnings on MondayCellular Biomedicine Group (CBMG) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Contrasting Cellular Biomedicine Group (CBMG) & Spring Bank Pharmaceuticals (SBPH)Contrasting Cellular Biomedicine Group (CBMG) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - March 3 at 11:48 AM
Zacks: Cellular Biomedicine Group Inc (CBMG) Given Average Rating of "Hold" by BrokeragesZacks: Cellular Biomedicine Group Inc (CBMG) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 2 at 7:24 PM
Cellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech FestivalCellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech Festival
finance.yahoo.com - March 1 at 9:21 AM
 Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Hold" from Brokerages Cellular Biomedicine Group Inc (CBMG) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 11 at 1:18 PM
 Cellular Biomedicine Group Inc (CBMG) Receives Average Rating of "Hold" from Analysts Cellular Biomedicine Group Inc (CBMG) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 8 at 7:36 PM
BRIEF-Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas InvestmentBRIEF-Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas Investment
www.reuters.com - February 6 at 4:33 PM
Cellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.Cellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.
finance.yahoo.com - February 5 at 9:00 AM
BRIEF-Cellular Biomedicine Announces Plan To Configure Part Of Shanghai FacilityBRIEF-Cellular Biomedicine Announces Plan To Configure Part Of Shanghai Facility
www.reuters.com - January 18 at 5:07 PM
CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish SolutionCBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution
finance.yahoo.com - January 18 at 5:07 PM
Cellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 SharesCellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 Shares
www.americanbankingnews.com - December 28 at 5:16 PM
Cellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 SharesCellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 Shares
www.americanbankingnews.com - December 28 at 5:10 PM
Insider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of StockInsider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of Stock
www.americanbankingnews.com - December 28 at 3:42 PM
ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:37 PM
Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement OfferingCellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering
finance.yahoo.com - December 28 at 12:37 PM
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:04 PM
BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
www.reuters.com - November 11 at 11:52 AM
Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint LaboratoryCellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
finance.yahoo.com - November 7 at 7:56 PM
BRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processesBRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
www.reuters.com - November 6 at 6:11 PM
Cellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing systemCellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing system
seekingalpha.com - November 6 at 6:11 PM
Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing ProcessesThermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
finance.yahoo.com - November 6 at 6:11 PM
Contrasting Cellular Biomedicine Group (CBMG) and Its PeersContrasting Cellular Biomedicine Group (CBMG) and Its Peers
www.americanbankingnews.com - November 6 at 3:15 PM
Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in LondonCellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
finance.yahoo.com - October 31 at 6:09 PM

SEC Filings

Cellular Biomedicine Group (NASDAQ:CBMG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellular Biomedicine Group (NASDAQ:CBMG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellular Biomedicine Group (NASDAQ CBMG) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.